Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Devimistat + Bendamustine in Relapsed/Refractory T-Cell NHL or Classic HL
NCT02168140Phase 1Completed
- Sponsor
- Wake Forest University Health Sciences
- Start
- Sep 2014
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of devimistat in T-cell non-Hodgkin lymphoma and Classical Hodgkin Lymphoma (cHL), sponsored by Wake Forest University Health Sciences. Primary endpoint: Maximum Tolerated Dose at 28 days. Started Sep 2014; status: completed.
02
Drugs
devimistat
03
Conditions
T-cell non-Hodgkin lymphomaClassical Hodgkin Lymphoma (cHL)
Beyond the preview
Go deeper on NCT02168140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02168140.